Work

Síndrome do Anticorpo Antifosfolipídeo em pacientes obstétricas: Uma revisão

Year: 2022
Type: article
Abstract: Antiphospholipid Antibody Syndrome (APAS), or Hughes Disease, is a systemic autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL), such as anticardiolipin antibodies (aCL), anti-β2-glycoprotein 1 (β2GPI) antibodies and lupus anticoagulant (LA). Cardiac, hematological, obstetric, nephrological and neurological manifestations are part of the clinical picture of the pathology. Obstetric patients with APS are prone to develop spontaneous abortions, fetal death or preterm delivery due to intrauterine growth restriction (IUGR), preeclampsia toxemia (PTE), eclampsia and other consequences of placental insufficiency. In this sense, pregnant women need drug therapy in order to avoid such complications during pregnancy. Therefore, the aim of the study is to discuss the antiphospholipid antibody syndrome in obstetric patients. This is an integrative literature review, which used the PubMed, SciELO and Cochrane Library platforms as databases for the selection of scientific articles, in English. According to the literature analyzed, obstetric complications can be treated using vitamin K antagonists, heparin and antiplatelet therapy, such as low-dose aspirin. Pravastatin is effective in the treatment of blood pressure and proteinuria, in addition to improving placental perfusion, with reduced risk of preeclampsia. Hydroxychloroquine prevents thrombotic phenomena and complications in pregnancy, as well as Certolizumab, which inhibits tumor necrosis factor alpha (TNF-????), responsible for the inflammatory reaction of APS.
Source: E-Acadêmica
Language: Portuguese
Subfield: Rheumatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W4285025643
FWCI:
Cites: 3
Cited by:
Related to: 10